IL6 and prostate carcinoma: In contrast, race-specific differences were observed for significantly higher serum levels of CXCL2 (p < 0.0001), CXCL5 (p = 0.016), and IL-6 (p = 0.004), and lower levels of CCL23 (p < 0.0001) and CCL27 (p = 0.016) in AA prostate cancer patients (n = 14) compared to CA (n = 14).